CG Oncology, Inc. Increase (Decrease) in Accrued Liabilities
CG Oncology, Inc. (CGON) reported Increase (Decrease) in Accrued Liabilities of -$4.13 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Financial Statements › Statement of Cash Flows › Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation › Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation › Cash Provided by (Used in) Operating Activity, Including Discontinued Operation › Cash Provided by (Used in) Operating Activity, Continuing Operation › Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity › Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital › Increase (Decrease) in Operating Liabilities › Increase (Decrease) in Accounts Payable and Accrued Liabilities › Increase (Decrease) in Accrued Liabilities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2024-05-09
- CG Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2024-03-31 was -$4.13M, a 2713.29% decline year-over-year.
- CG Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was $158.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month |
|---|---|
| 2024-03-31 | -$4.13M 10-Q · filed 2024-05-09 |
| 2023-03-31 | $158.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |